The company will collaborate with Rutgers University to test ProSyn as a tool for the production of therapeutic small molecules to respond to biological threats and pandemics.
SRI International, a non-profit research institute, has been awarded $4.3 million from the Defense Advanced Research Projects Agency (DARPA) to develop ProSyn, a deployable extension of SynFini, SRI’s fully automated synthetic chemistry system.
The company will collaborate with Rutgers University’s Department of Chemical and Biological Engineering and Center for Structured Organic Particulate Systems to test ProSyn as a tool for the production of therapeutic small molecules to respond to biological threats and pandemics, an October 7, 2020 company press release said. ProSyn will be dedicated to translating processes created on the SynFini to desired production levels to provide scalable manufacturing capacity.
“Throughout the COVID-19 pandemic, it has become overwhelmingly clear that there is a desperate need for technologies that can quickly discover therapeutics against new infectious diseases and, importantly, rapidly manufacture them at scale to make them broadly available,” said Nathan Collins, PhD, chief strategy officer of SRI’s Biosciences division and the principal investigator for the ProSyn project, in the press release. “With the addition of ProSyn, the SynFini suite may be able to address both needs. We are grateful to DARPA for recognizing this and subsequently supporting the ProSyn project, which could enable more effective response to pandemics such as COVID-19 and other biological threats.”
Source: SRI
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.